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Abstract 
Background: Patient with neurological disorders and cancer can develop sleep disturbance, in particular insomnia. 
Etiology of insomnia is multi-factorial in primary brain tumour patients with possible causes including corticosteroids, 
psychoactive medications, co-morbid psychiatric/medical conditions, and damage to neuronal tissue.
Findings: To understand better insomnia in recurrent glioma patients, a single-center retrospective analysis was 
performed looking at recurrent glioma patients from January 2004 to May 2009. Data was extracted and included 
demographics, clinical factors, psychoactive medications, and co-morbid symptoms. Presence and absence of insom-
nia complaints was evaluated with other co-morbidities using Chi square and Wilcoxon analyses. Records from 340 
recurrent glioma patients were evaluated and 46.8 % (n = 159) indicated presence of insomnia with 20 % (n = 66) 
actively using medications for sleep. Use of corticosteroids were significantly associated with insomnia (p = 0.0003). 
Age, gender, tumour location, use of stimulants, antipsychotics, and antidepressants were not significantly associated 
with insomnia in recurrent glioma patients. There was a trend towards a possible significant association with insomnia 
to fatigue complaints and use of anti-epileptics, p-values of 0.0501 and 0.0725 respectively.
Conclusions: In conclusion, insomnia is commonly encountered in patients with recurrent glial tumors. Corticoster-
oid use is associated with insomnia in this population. In light of the frequency of insomnia and its associations, future 
analysis is warranted into sleep complaints in recurrent glioma patients and its impact on quality of life.
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Findings
Background
Primary brain tumours represent 1  % of all diagnosed 
cancers (Ohgaki 2009). In studies in regards to quality 
of life in patients with primary brain tumours, insom-
nia is commonly seen (Taphoorn and Bottomley 2005; 
Taphoorn et  al. 2005). This problem not only occurs in 
high-grade patients but also in patients with low-grade 
tumours (Gustafsson et al. 2006). In a study by Wellisch 
and colleagues, they evaluated the incidence of major 
depressive disorder in patients with primary brain 
tumours and also found that sleep dysfunction was pre-
sent in over 50 % of these patients (Wellisch et al. 2002). 
While sleep dysfunction often accompanies depression, 
insomnia could be multifactorial in primary brain tumour 
patients. Chemotherapy, radiotherapy, use of corticoster-
oids such as dexamethasone, use of antiepileptics (AEDs) 
and psychoactive medications, and damage to the brain 
parenchyma either by tumour or surgery could have an 
impact on sleep architecture. One important question 
that has been considered is how to treat properly insom-
nia in patients with primary brain tumours as many of the 
sleep inducing agents can lead to cognitive difficulty that 
leads to interference with the quality of life. Therefore, we 
sought to evaluate complaints of insomnia in recurrent 
glioma patients and its associations with patient, tumour, 
medication, and co-morbid symptoms.
Methods
This was retrospective single-center study to evalu-
ate insomnia and its associations in recurrent glioma 
patients at the Preston Robert Tisch Brain Tumor Center 
at Duke from January 1, 2006 to May 1, 2009. This study 
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was reviewed and managed by the Duke Institutional 
Review Board; this study was deemed to be retrospec-
tive and did not require patient consent. The clinical 
charts of patients that were enrolled in clinical treatment 
protocols for recurrent glial neoplasms were reviewed. 
These data reviewed were collected as part of medical 
care and retrospectively queried. In clinical treatment 
protocols for recurrent glial tumors, adverse events have 
been collected using Common Terminology Criteria for 
Adverse Events (CTCAE), and insomnia was selected as 
the adverse event to study for this retrospective analysis. 
Insomnia was captured using the CTCAE version 3 and 
defined as a disorder characterized by difficulty falling 
asleep and/or remaining asleep. Severity of insomnia was 
graded and included mild (occasional difficulty sleep-
ing, not interfering with function), moderate (difficulty 
sleeping, interfering with function and not interfering 
with activities of daily living), and severe (frequent dif-
ficulty sleeping, interfering with activities of daily liv-
ing). Patients were defined as having insomnia present 
or absent. Moreover, subjects in these clinical trials were 
always queried in regards to the presence of insomnia. 
Additional data were obtained from medical records and 
included demographics (age, gender, race, tumour grade, 
location of tumour), Karnofsky performance score (KPS), 
number of prior progressions, sleep complaints (such as 
insomnia, snoring, nightmares, restless legs), sleep dis-
orders (such as obstructive sleep apnea, REM behavioral 
disorder, restless leg syndrome, narcolepsy), corticos-
teroid use, AED use, psychoactive medication use, and 
comorbid symptoms (such as depression, fatigue, and 
cognitive dysfunction). Of note, KPS is a 0–100 scale 
used to describe the performance and function of can-
cer patients in regards to activities of daily living. The 
rationale for this was to look for associations of these 
previous pieces of information with the presence and 
absence of insomnia. Descriptive analysis was performed 
on all demographic, medication and symptom variables. 
Insomnia was treated as a binary variable (absent or pre-
sent) and the following statistical tests were performed: 
1. Chi square test for gender, race, tumour grade, side of 
brain, KPS, number of progressions, corticosteroid use, 
antidepressant use, stimulant use, sleep aid use, antip-
sychotic use, AED use, and co-morbid symptoms and 2. 
Wilcoxon analysis for age. The level of significance was 
set at p-value <0.05.
Results
Charts from 340 recurrent glioma patients were reviewed 
retrospectively. Data is presented in Table  1. In brief, 
the mean  ±  standard deviation age was 48.4  years 
(11.7  years), 225 (66.2  %) were male, and majority 
(n  =  322, 94.7  %) were Caucasian. In terms of tumour 
grade, 296 (87.1  %) were high-grade gliomas and 44 
(12.9  %) were low-grade gliomas. At the time that the 
data was extracted, a majority of recurrent glioma 
patients had only one progression (n = 178, 52.4 %) and 
had KPS of 90–100 (n = 169, 50.6 %). Insomnia was doc-
umented as a complaint in the medical record for 159 
(46.8  %) recurrent glioma patients. Gender, race, and 
tumour grade were not associated with the presence of 
insomnia in this patient population.
There was also no statistically significant observed dif-
ference in KPS scale amongst dichotomized insomnia 
groups (p-value of 0.0793). Ninety-eight (55  %) patients 
without insomnia had KPS scores of 90-100 while 71 
(45 %) patients with insomnia had similar scores. Patients 
with KPS scores from 50 to 80 ranged from 79 (45 %) in 
the insomnia absent cohort, to 86 (55 %) in the insomnia 
present cohort.
Tumour progression is defined radiographically by 
increased tumor growth on magnetic resonance imag-
ing (MRI). The association between progression of the 
tumour and the presence or absence of insomnia was 
investigated. Patients with one progression were similarly 
represented in the insomnia absent group (91 patients or 
50 %) compared with 87 (55 %) patients in the insomnia 
present cohort. Fifty-one (28  %) patients had 2 tumour 
progressions without evidence of insomnia, while 46 
(29 %) did endorse insomnia. Three or more tumour pro-
gressions were documented in 39 (22 %) patients without 
insomnia and 26 (16 %) patients with insomnia. A rela-
tion between an increasing number of tumour progres-
sions and insomnia did not meet statistical significance 
(p-value 0.4868).
Corticosteroid use was found to significantly impact 
sleep leading to insomnia. Of the patients on steroid 
therapy, 59 (33 %) did not have insomnia symptoms while 
83 (52  %) had sleep disturbance, reaching a p-value of 
0.0003. When further stratified into insomnia severity 
47 % (55 patients) endorsed mild insomnia while taking 
steroids. In patients with moderate insomnia, 57  % (17 
patients) were using steroids. Severe insomnia correlated 
with steroid use in 85 % (11) patients, reaching a p-value 
of 0.0001.
AED use trended towards statistical significance 
(p-value of 0.0725) with 131 patients (72  %) without 
insomnia taking antiepileptic medication, while 129 
(81 %) of those with insomnia were taking some form of 
AED. Grouping insomnia complaints by the number of 
AEDs taken demonstrated that in patients with insomnia 
19 % were prescribed no AED, 59 % were taking one AED 
and 22 % were prescribed two or more AEDs.
Chi Square analyses were employed to look at several 
subjective complaints common in the primary brain 
tumour population in an attempt to correlate presence of 
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 N 181 159 340
 Median 50.0 50.0 50.0
Gender 0.9087
 Male 119 (65.7 %) 106 (66.7 %) 225 (66.2 %)
 Female 62 (34.3 %) 53 (33.3 %) 115 (33.8 %)
Race 0.8122
 Caucasian 172 (95.0 %) 150 (94.3 %) 322 (94.7 %)
 Other race 9 (5.0 %) 9 (5.7 %) 18 (5.3 %)
Histology 0.1483
 High-grade glioma 153 (84.5 %) 143 (89.9 %) 296 (87.1 %)
 Low-grade glioma 28 (15.5 %) 16 (10.1 %) 44 (12.9 %)
Side of brain affected 0.1585
 Right 83 (45.9 %) 80 (50.3 %) 163 (47.9 %)
 Left 82 (45.3 %) 73 (45.9 %) 155 (45.6 %)
 Bilateral 16 (8.8 %) 6 (3.8 %) 22 (6.5 %)
KPS 0.0793
 50–80 79 (44.6 %) 86 (54.8 %) 165 (49.4 %)
 90–100 98 (55.4 %) 71 (45.2 %) 169 (50.6 %)
Number of progressions 0.4868
 1 91 (50.3 %) 87 (54.7 %) 178 (52.4 %)
 2 51 (28.2 %) 46 (28.9 %) 97 (28.5 %)
 3+ 39 (21.5 %) 26 (16.4 %) 65 (19.1 %)
Corticosteroid use 0.0003
 Yes 59 (32.6 %) 83 (52.2 %) 142 (41.8 %)
 No 122 (67.4 %) 76 (47.8 %) 198 (58.2 %)
Antidepressant use >0.999
 Yes 53 (29.3 %) 46 (28.9 %) 99 (29.1 %)
 No 128 (70.7 %) 113 (71.1 %) 241 (70.9 %)
Stimulant use >0.999
 Yes 15 (8.3 %) 14 (8.8 %) 29 (8.5 %)
 No 166 (91.7 %) 145 (91.2 %) 311 (91.5 %)
Sleep aid use 0.0764
 Yes 29 (16.0 %) 38 (23.9 %) 67 (19.7 %)
 No 152 (84.0 %) 121 (76.1 %) 273 (80.3 %)
Antipsychotic use >0.999
 Yes 3 (1.7 %) 2 (1.3 %) 5 (1.5 %)
 No 178 (98.3 %) 157 (98.7 %) 335 (98.5 %)
Anti-epileptic use 0.0725
 Yes 131 (72.4 %) 129 (81.1 %) 260 (76.5 %)
 No 50 (27.6 %) 30 (18.9 %) 80 (23.5 %)
Symptom: fatigue 0.0501
 Absent 33 (18.2 %) 17 (10.7 %) 50 (14.7 %)
 Present 148 (81.8 %) 142 (89.3 %) 290 (85.3 %)
Symptom: sedation 0.8895
 Absent 131 (72.4 %) 114 (71.7 %) 245 (72.1 %)
 Present 50 (27.6 %) 45 (28.3 %) 95 (27.9 %)
Symptom: confusion 0.5697
 Absent 127 (70.2 %) 116 (73.0 %) 243 (71.5 %)
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these symptoms with insomnia. In patients with insom-
nia, there was no statistically significant association 
between documented symptoms of sedation, confusion, 
and mood disturbance. In regards to the relationship 
between fatigue and insomnia, there was a trend to sig-
nificance. Of the 159 patients endorsing some degree of 
insomnia, 142 (89 %) also complained of fatigue. p-value 
for this relationship was close to significance at 0.0501.
Discussion
Sleep disturbance in the form of insomnia remains a 
major quality of life concern in primary glioma patients. 
In this retrospective analysis of glioma patients common 
tumour variables, co-morbid medications, and subjective 
patient complaints were analyzed as to their roles in caus-
ing insomnia. Insomnia is an often minimized, but com-
mon symptom in all patients. Insomnia rates amongst 
healthy adult individuals are 13–33  % (Kaye et  al. 1983; 
Cunnington et  al. 2013). In contrast, cancer of any kind 
has been associated with 30–50 % insomnia rates in newly 
diagnosed patients, and in 23–44  % of cancer patients 
2–5 years after initial diagnosis (Savard and Morin 2001; 
Savard et al. 2001, 2009). Insomnia in patients with cancer 
can be precipitated by many factors both from the cancer 
itself or its treatment (Savard et al. 2015).
Corticosteroid use has been associated with many side 
effects, including insomnia. Unfortunately, corticosteroid 
therapy is often a necessary treatment in the treatment of 
CNS neoplasms. A recent study demonstrated an insom-
nia rate of 22 % in patients being treated for brain metas-
tases (Sturdza et  al. 2008). No study to date has looked 
at insomnia related to corticosteroid use in a primary 
brain tumour population. In our current study, there is a 
clear relationship between corticosteroid use and insom-
nia. Eighty-three of the 142 total patients taking steroids 
(52 %) related some degree of insomnia. This represents 
a higher incidence of insomnia compared to the brain 
metastasis steroid users, which may relate to differences 
in amount of corticosteroid given, differing concomitant 
therapies or different underlying disease processes. There 
was also a relatively high percentage (47  %) of patients 
not prescribed corticosteroids who related symptoms 
of insomnia. This again may relate to disruption of cir-
cadian rhythms due to tumour location, burden of 
psychosocial pressures, or secondary to other therapeutic 
interventions.
While AED use associated with insomnia trended 
towards statistical significance in our glioma group, the 
multitude of pharmacologic options and varying phar-
macologic mechanisms make a general analysis of this 
population difficult. Prior studies have looked at specific 
AEDs and their effects on sleep in healthy patients and 
those with underlying epilepsy. Antiepileptic classes such 
as benzodiazepines and barbiturates have been found to 
have detrimental effects on sleep (Bazil 2003). Barbiturates 
can decrease sleep latency and increase sleep continuity 
(Obermeyer and Benca 1996), but long term use has actu-
ally been associated with insomnia and depressed REM 
sleep (Wolf et al. 1984). Benzodiazepines have been found 
to decrease slow-wave sleep with prolonged use and with-
drawal is associated with insomnia. Phenytoin decreases 
sleep latency, but has been associated with increased noc-
turnal awakenings and reduced REM sleep (Legros and 
Bazil 2003). Interestingly, gabapentin and lamotrigine 
have both been shown to increase REM sleep (Placidi et al. 
2000). Levetiracetam was found to have no effect on num-
ber of awakenings, sleep efficiency or amount of REM, 
but patients subjectively perceive fewer awakenings, more 
restful sleep and decreased alertness in awakening.
Fatigue is also a common symptom both within the 
cancer population as a whole, and among patients with 
primary brain tumours. In a same by Kim et al. a linear 
regression analysis of sleep disturbance in the form of 
insomnia was a strong predictor of fatigue as scored on a 
Brief Fatigue Inventory (Kim et al. 2012). In the primary 
brain tumour patient cohort studied in this retrospective 
analysis, insomnia again proved to be a strong predic-
tor of fatigue with over 89  % of patients with insomnia 
endorsing fatigue.
In conclusion, our retrospective analysis showed that 
insomnia is a common complaint in recurrent glioma 
patients, irrespective of grade, and is significantly asso-
ciated with use of corticosteroids. Discussion of other 
concomitant medications, such as AEDs, and co-mor-
bid symptoms, such as fatigue, should be performed in 
patients endorsing insomnia. Evaluation and treatment of 
insomnia and how it impacts a patient’s quality of life is 







 Present 54 (29.8 %) 43 (27.0 %) 97 (28.5 %)
Symptom: mood disturbance 0.2438
 Absent 107 (59.1 %) 84 (52.8 %) 191 (56.2 %)
 Present 74 (40.9 %) 75 (47.2 %) 149 (43.8 %)
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